Trevigen's Directed In Vivo Angiogenesis Assay (Divaa) is the first in vivo system for the study of angiogenesis that provides quantitative and reproducible results.
Divaa has been used in evaluating the inhibition of angiogenesis in matrix metalloprotease (MMP)-2-deficient mice and by Timp-2 and enhancement of angiogenesis associated with adrenomedullin and CD97.
The Divaa inhibition kit was developed for screening inhibitors of angiogenesis; to this end, ample growth factor is provided for all 48 angioreactors.
